COSYNTROPIN

Post-LOE

cosyntropin

Novartis

ANDAINJECTIONINJECTABLE

Approved

Jun 2012

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

COSYNTROPIN (cosyntropin) by Novartis is acth. Approved for adrenocorticotropic hormone [epc]. First approved in 2012.

Drug data last refreshed 20h ago

Mechanism of Action

ACTH. Various studies have shown that the biologic activity of ACTH resides in the N-terminal portion of the molecule and that the 1-20 amino acid residue is the minimal sequence retaining full activity. Partial or complete loss of activity is noted with progressive shortening of the chain beyond…

Pharmacologic Class:

Adrenocorticotropic Hormone

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (1)

NCT02394457Phase 4Completed

Cosyntropin Versus Epidural Blood Patch (EBP) for Treatment of Treatment of Post Dural Puncture Headache

Started Aug 2010

29 enrolled

Postdural Puncture Headache

Company

Worked on COSYNTROPIN at Novartis? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.